SCHEDULE: Citadel Discloses 4.9% Stake in Acrivon Therapeutics
Beneficial Ownership Report
Citadel and its affiliates, including Kenneth Griffin, report a 4.9% passive beneficial ownership in Acrivon Therapeutics, Inc. as of September 30, 2025.
Summary
- Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC collectively beneficially own 1,541,326 shares of Acrivon Therapeutics, Inc. Common Stock, representing 4.9% of the class.
- Citadel Securities LLC, Citadel Securities Group LP, and Citadel Securities GP LLC collectively beneficially own 39 shares, representing 0.0% of the class.
- Kenneth Griffin, through his control over the various Citadel entities, is deemed to beneficially own an aggregate of 1,541,365 shares, also representing 4.9% of the class.
- The beneficial ownership is reported as of September 30, 2025.
- The percentages are based on 31,455,645 shares outstanding as of August 8, 2025, according to the issuer's Form 10-Q filed on August 13, 2025.
- The filing indicates that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: This is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or prospects.
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investment by Citadel in Acrivon Therapeutics, a common occurrence in the biotechnology and pharmaceutical sectors where institutional funds often take positions in companies with promising pipelines or market potential. Such investments can signal institutional confidence, though this specific filing is for passive ownership.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor like Citadel taking a 4.9% stake could be viewed positively, potentially increasing market confidence and liquidity for Acrivon Therapeutics shares.
Key Dates
| Date | Description |
|---|---|
| 2025-08-08 | Date of shares outstanding calculation (31,455,645 shares) for Acrivon Therapeutics, Inc. |
| 2025-08-13 | Date Acrivon Therapeutics, Inc. filed its Form 10-Q with the SEC. |
| 2025-09-30 | Date of event which requires filing of this statement (beneficial ownership reporting date). |
| 2025-11-14 | Date the Schedule 13G was signed and filed. |
Keywords
Acrivon Therapeutics, Citadel, Kenneth Griffin, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.